Journal article
Risk Factors for Treatment Failure With Antiosteoporosis Medication: The Global Longitudinal Study of Osteoporosis in Women (GLOW)
Abstract
Antiosteoporosis medication (AOM) does not abolish fracture risk, and some individuals experience multiple fractures while on treatment. Therefore, criteria for treatment failure have recently been defined. Using data from the Global Longitudinal Study of Osteoporosis in Women (GLOW), we analyzed risk factors for treatment failure, defined as sustaining two or more fractures while on AOM. GLOW is a prospective, observational cohort study of …
Authors
Díez‐Pérez A; Adachi JD; Adami S; Anderson FA; Boonen S; Chapurlat R; Compston JE; Cooper C; Gehlbach SH; Greenspan SL
Journal
Journal of Bone and Mineral Research, Vol. 29, No. 1, pp. 260–267
Publisher
Oxford University Press (OUP)
Publication Date
January 1, 2014
DOI
10.1002/jbmr.2023
ISSN
0884-0431